Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844407 | 0.85 | MAPT (0.48) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL4678156 | 0.84 | KDM4E (0.52) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL28957583 | 0.80 | MEN1 (0.47) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL25399698 | 0.80 | MAPT (0.57) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL7718402 | 0.80 | KDM4E (0.52) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL2805013 | 0.80 | KDM4E (0.52) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL12775851 | 0.79 | KDM4E (0.47) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL20744401 | 0.79 | KDM4E (0.47) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL13197096 | 0.79 | KDM4E (0.47) | KMT2AMEN1KDM4EMAPTHSD17B10 | |
| SCHEMBL13940123 | 0.79 | ALDH1A1 (0.49) | KMT2AMEN1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021116541-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2021-06-17 | — | — | WO | disclosed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8829204-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8741925-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100249349-A1 | Novel Polymers | UDC IRELAND LIMITED (IE) | 2010-09-30 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | KMT2A 4711/4885MEN1 2917/4885KDM4E 4759/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4245/4885MEN1 4698/4885KDM4E 4262/4885 |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | KMT2A 87/4885MEN1 3742/4885KDM4E 903/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KMT2A 4344/4885MEN1 4698/4885KDM4E 4337/4885 |
| US-20100249349-A1 | Novel Polymers | OCIAD2, OCIAD1, SLCO4C1 | KMT2A 3980/4885MEN1 4502/4885KDM4E 3738/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | KMT2A 3685/4885MEN1 4835/4885KDM4E 3625/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4245/4885MEN1 4698/4885KDM4E 4262/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | KMT2A 4546/4885MEN1 4778/4885KDM4E 4552/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | KMT2A 2222/4885MEN1 4860/4885KDM4E 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.